Remestemcel-L-rknd (Ryoncil): the first approved cellular therapy for steroid-refractory acute GVHD

2.

Etra

A

,

Gergoudis

S

,

Morales

G

, et al.

Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification

.

Blood Adv

.

2022

;

6

(

12

):

3707

-

3715

.

3.

McDonald

GB

,

Sandmaier

BM

,

Mielcarek

M

, et al.

Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts

.

Ann Intern Med

.

2020

;

172

(

4

):

229

-

239

.

4.

Merli

P

,

Pagliara

D

,

Galaverna

F

, et al.

TCRαβ/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders

.

Blood Adv

.

2022

;

6

(

1

):

281

-

292

.

5.

Watkins

B

,

Qayed

M

,

McCracken

C

, et al.

Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD

.

J Clin Oncol

.

2021

;

39

(

17

):

1865

-

1877

.

6.

Andolina

JR

,

Wang

YC

,

Ji

L

, et al.

Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children's Oncology Group experience

.

Bone Marrow Transpl

.

2022

;

57

(

3

):

445

-

452

.

7.

Qayed

M

,

Wang

T

,

Hemmer

MT

, et al.

Influence of age on acute and chronic GVHD in children undergoing HLA-identical sibling bone matrow transplantation for acute leukemia: Implications for prophylaxis

.

Biol Blood Marrow Transpl

.

2018

;

24

(

3

):

521

-

528

.

8.

Reshef

R

,

Saber

W

,

Bolaños-Meade

J

, et al.

Acute GVHD diagnosis and adjudication in a multicenter trial: a report from the BMT CTN 1202 biorepository study

.

J Clin Oncol

.

2021

;

39

(

17

):

1878

-

1887

.

9.

Davies

SM

,

Wang

D

,

Wang

T

, et al.

Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants

.

Biol Blood Marrow Transpl

.

2009

;

15

(

3

):

360

-

366

.

10.

Gergoudis

SC

,

DeFilipp

Z

,

Özbek

U

, et al.

Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin

.

Blood Adv

.

2020

;

4

(

24

):

6098

-

6105

.

11.

MacMillan

ML

,

Robin

M

,

Harris

AC

, et al.

A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality

.

Biol Blood Marrow Transpl

.

2015

;

21

(

4

):

761

-

767

.

12.

Zeiser

R

,

von Bubnoff

N

,

Butler

J

, et al.

Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease

.

N Engl J Med

.

2020

;

382

(

19

):

1800

-

1810

.

13.

DeFilipp

Z

,

Kim

HT

,

Spyrou

N

, et al.

The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD

.

Blood Adv

.

2024

;

8

(

13

):

3488

-

3496

.

14.

von Bubnoff

N

,

Ihorst

G

,

Grishina

O

, et al.

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

.

BMC Cancer

.

2018

;

18

(

1

):

1132

.

15.

Søborg

A

,

Reekie

J

,

Sengeløv

H

, et al.

Trends in underlying causes of death in allogeneic hematopoietic cell transplant recipients over the last decade

.

Eur J Haematol

.

2024

;

112

(

5

):

802

-

809

.

16.

Le Blanc

K

,

Rasmusson

I

,

Sundberg

B

, et al.

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

.

Lancet

.

2004

;

363

(

9419

):

1439

-

1441

.

17.

Jossen

V

,

van den Bos

C

,

Eibl

R

,

Eibl

D

.

Manufacturing human mesenchymal stem cells at clinical scale: process and regulatory challenges

.

Appl Microbiol Biotechnol

.

2018

;

102

(

9

):

3981

-

3994

.

18.

Soder

RP

,

Dawn

B

,

Weiss

ML

, et al.

A phase I study to evaluate two doses of Wharton's Jelly-derived mesenchymal stromal cells for the treatment of de novo high-risk or steroid-refractory acute graft versus host disease

.

Stem Cell Rev Rep

.

2020

;

16

(

5

):

979

-

991

.

19.

Li

Y

,

Hao

J

,

Hu

Z

, et al.

Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review

.

Stem Cell Res Ther

.

2022

;

13

(

1

):

93

.

20.

Kurtzberg

J

,

Prockop

S

,

Chaudhury

S

, et al.

Study 275: updated expanded access program for remestemcel-L in steroid-refractory acute graft-versus-host disease in children

.

Biol Blood Marrow Transpl

.

2020

;

26

(

5

):

855

-

864

.

21.

Bukauskas

A

,

Jucaitienė

R

,

Stoškus

M

, et al.

Mesenchymal stromal cells for steroid-refractory biopsy-proven grade III-IV acute graft-versus-host disease with predominant gastrointestinal involvement

.

Front Immunol

.

2025

;

16

:

1600019

.

22.

Galleu

A

,

Milojkovic

D

,

Deplano

S

, et al.

Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival

.

Br J Haematol

.

2019

;

185

(

1

):

89

-

92

.

23.

Kebriaei

P

,

Hayes

J

,

Daly

A

, et al.

A phase 3 randomized study of remestemcel-L versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease

.

Biol Blood Marrow Transpl

.

2020

;

26

(

5

):

835

-

844

.

24.

Kurtzberg

J

,

Abdel-Azim

H

,

Carpenter

P

, et al.

A phase 3, single arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease

.

Biol Blood Marrow Transpl

.

2020

;

26

(

5

):

845

-

854

.

25.

Le Blanc

K

,

Frassoni

F

,

Ball

L

, et al.

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

.

Lancet

.

2008

;

371

(

9624

):

1579

-

1586

.

26.

Murata

M

,

Terakura

S

,

Wake

A

, et al.

Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence

.

Bone Marrow Transpl

.

2021

;

56

(

10

):

2355

-

2366

.

27.

Muroi

K

,

Miyamura

K

,

Okada

M

, et al.

Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study

.

Int J Hematol

.

2016

;

103

(

2

):

243

-

250

.

28.

Niu

JW

,

Li

Y

,

Xu

C

, et al.

Human umbilical cord-derived mesenchymal stromal cells for the treatment of steroid refractory grades III-IV acute graft-versus-host disease with long-term follow-up

.

Front Immunol

.

2024

;

15

:

1436653

.

29.

Resnick

IB

,

Barkats

C

,

Shapira

MY

, et al.

Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC)

.

Am J Blood Res

.

2013

;

3

(

3

):

225

-

238

.

30.

Bonig

H

,

Kuçi

Z

,

Kuçi

S

, et al.

Children and adults with refractory acute graft-versus-host disease respond to treatment with the mesenchymal stromal cell preparation “MSC-FFM”-outcome report of 92 patients

.

Cells

.

2019

;

8

(

12

):

1577

.

31.

Dominici

M

,

Le Blanc

K

,

Mueller

I

, et al.

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

.

Cytotherapy

.

2006

;

8

(

4

):

315

-

317

.

32.

Waterman

RS

,

Tomchuck

SL

,

Henkle

SL

,

Betancourt

AM

.

A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype

.

PLoS One

.

2010

;

5

(

4

):

e10088

.

33.

Krampera

M

,

Glennie

S

,

Dyson

J

, et al.

Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide

.

Blood

.

2003

;

101

(

9

):

3722

-

3729

.

34.

Ren

G

,

Su

J

,

Zhang

L

, et al.

Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression

.

Stem Cells

.

2009

;

27

(

8

):

1954

-

1962

.

35.

Giacomini

C

,

Granéli

C

,

Hicks

R

,

Dazzi

F

.

The critical role of apoptosis in mesenchymal stromal cell therapeutics and implications in homeostasis and normal tissue repair

.

Cell Mol Immunol

.

2023

;

20

(

6

):

570

-

582

.

36.

Bernardo

ME

,

Fibbe

WE

.

Mesenchymal stromal cells: sensors and switchers of inflammation

.

Cell Stem Cell

.

2013

;

13

(

4

):

392

-

402

.

37.

Mougiakakos

D

,

Jitschin

R

,

Johansson

CC

,

Okita

R

,

Kiessling

R

,

Le Blanc

K

.

The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells

.

Blood

.

2011

;

117

(

18

):

4826

-

4835

.

38.

Ringdén

O

,

Moll

G

,

Gustafsson

B

,

Sadeghi

B

.

Mesenchymal stromal cells for enhancing hematopoietic engraftment and treatment of graft-versus-host disease, hemorrhages and acute respiratory distress syndrome

.

Front Immunol

.

2022

;

13

:

839844

.

39.

Schrepfer

S

,

Deuse

T

,

Reichenspurner

H

,

Fischbein

MP

,

Robbins

RC

,

Pelletier

MP

.

Stem cell transplantation: the lung barrier

.

Transpl Proc

.

2007

;

39

(

2

):

573

-

576

.

40.

Wang

S

,

Guo

L

,

Ge

J

, et al.

Excess integrins cause lung entrapment of mesenchymal stem cells

.

Stem Cells

.

2015

;

33

(

11

):

3315

-

3326

.

41.

Németh

K

,

Leelahavanichkul

A

,

Yuen

PS

, et al.

Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production

.

Nat Med

.

2009

;

15

(

1

):

42

-

49

.

42.

Merimi

M

,

El-Majzoub

R

,

Lagneaux

L

, et al.

The therapeutic potential of mesenchymal stromal cells for regenerative medicine: Current knowledge and future understandings

.

Front Cell Dev Biol

.

2021

;

9

:

661532

.

43.

Jagasia

M

,

Perales

MA

,

Schroeder

MA

, et al.

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

.

Blood

.

2020

;

135

(

20

):

1739

-

1749

.

44.

Przepiorka

D

,

Luo

L

,

Subramaniam

S

, et al.

FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease

.

Oncologist

.

2020

;

25

(

2

):

e328

-

e334

.

45.

Locatelli

F

,

Kang

HJ

,

Bruno

B

, et al.

Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 study

.

Blood

.

2024

;

144

(

20

):

2095

-

2106

.

46.

Major-Monfried

H

,

Renteria

AS

,

Pawarode

A

, et al.

MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD

.

Blood

.

2018

;

131

(

25

):

2846

-

2855

.

47.

Akahoshi

Y

,

Spyrou

N

,

Weber

D

, et al.

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

.

Blood

.

2024

;

144

(

9

):

1010

-

1021

.

48.

Kasikis

S

,

Baez

J

,

Gandhi

I

, et al.

Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers

.

Bone Marrow Transpl

.

2021

;

56

(

11

):

2869

-

2870

.

49.

Zhao

K

,

Lin

R

,

Fan

Z

, et al.

Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial

.

J Hematol Oncol

.

2022

;

15

(

1

):

22

.